



(IMI KM call-topic 8, 2010)

www.openphacts.org

- **The Challenge - Open standards for drug discovery data**
 - Drug discovery research is increasingly data and information driven but we are **challenged to integrate content across domains (Chemistry, Biology, Clinical)**
 - Key content spread over many sources
 - Lack of agreed standards and formatting drives unsustainable efforts in content integration
 - Increasing volumes and privacy constraints (e.g. Biobanks) drives paradigm shift: We need to move analysis to data rather than retrieve data for analysis
- **Open PHACTS Project (28 partners: 9 pharma – 19 academic / SME)**
 - **Develop robust standards** for solid integration between data sources via semantic technologies
 - **Implement the standards** in a semantic integration hub (“Open Pharmacological Space”)
 - **Deliver services** to support on-going drug discovery programs in pharma and public domain
- **Benefit:**
 - **Reduced costs and improved access** to inter-operable drug discovery information
 - Work on-going with RSC/Chemspider on data-models for handling drug formulations, combinations and public sources; Source most public data directly from RSC/Chemspider in correct format
 - **Development of critical skills** and organisational learning
 - **Access to leading European labs** in semantic data, workflow analysis and information mining (U Manchester, VU Amsterdam, NBIC, Fraunhofer)
 - **Structured plan to align AZ scientists** within work-packages to directly exploit developments in on-going internal initiatives





Open PHACTS Project Partners

www.openphacts.org

Pfizer Limited – Coordinator

Universität Wien – Managing entity

Technical University of Denmark

University of Hamburg, Center for Bioinformatics

BioSolveIT GmbH

Consorti Mar Parc de Salut de Barcelona

Leiden University Medical Centre

Royal Society of Chemistry

Vrije Universiteit Amsterdam

Spanish National Cancer Research Centre

University of Manchester

Maastricht University

Aqnowledge

University of Santiago de Compostela

Rheinische Friedrich-Wilhelms-Universität Bonn

AstraZeneca

GlaxoSmithKline

Esteve

Novartis

Merck Serono

H. Lundbeck A/S

Eli Lilly

Netherlands Bioinformatics Centre

Swiss Institute of Bioinformatics

ConnectedDiscovery

EMBL-European Bioinformatics Institute

Janssen

OpenLink

